JNJ.N (JNJ.N) News
Track canonical SquawkNews coverage tagged to JNJ.N, JNJ.N. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
J&J's Caplyta meets main goal of bipolar mania study
Johnson & Johnson's experimental drug Caplyta met the main goal of a late-stage study for bipolar mania, showing a significant reduction in symptoms compared to placebo. The study also met a key secondary goal, with abou
EQUITY | Sep 21, 2026, 12:52 PM UTC
M
J&J's Caplyta shows rapid improvement in bipolar mania in Phase 3 study
Johnson & Johnson announced that its drug Caplyta (lumateperone) demonstrated a statistically significant and rapid reduction in manic symptoms at Week 3 in a pivotal Phase 3 study for bipolar mania. The drug was well-to
EQUITY | Sep 21, 2026, 12:38 PM UTC